<DOC>
	<DOCNO>NCT01596335</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TA-650 comparison control drug Polyethylene Glycol-treated Human Immunoglobulin ( VGIH ) patient Kawasaki disease refractory initial therapy Intravenous Immunoglobulin ( IVIG ) . The pharmacokinetics TA-650 also examine .</brief_summary>
	<brief_title>Clinical Study TA-650 Patients With Refractory Kawasaki Disease</brief_title>
	<detailed_description />
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients diagnose Kawasaki disease ( incipient case ) 5 6 major symptom Kawasaki disease . Patients refractory initial IVIG therapy ( single administration 2 g per kg body weight ) . Patients fever 37.5ºC high axillary temperature time enrollment . Patients study drug administer day 8 disease . Patients receive vaccination Bacille CalmetteGuérin ( BCG ) vaccine within 6 month enrollment . Patients complication , history within 6 month enrollment , serious infection require hospitalization . Patients complication , history within 6 month enrollment , opportunistic infection . Patients complicate active tuberculosis , active hepatitis B C , patient confirm hepatitis B virus carrier history hepatitis B . Patients confirm HIV infection , patient family history HIV infection . Patients history receive treatment infliximab biological product . Patients participate another clinical study receive study drug within 12 week give consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
	<keyword>intravenous immunoglobulin</keyword>
	<keyword>Kawasaki disease</keyword>
	<keyword>IVIG</keyword>
</DOC>